Skip to main content
Journal cover image

Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.

Publication ,  Journal Article
Dery, J-P; Campbell, ME; Mathias, J; Pieper, KS; Harrington, RA; Madan, M; Gibson, CM; Tolleson, TR; O'Shea, JC; Tcheng, JE; ESPRIT Investigators,
Published in: Catheter Cardiovasc Interv
July 1, 2007

OBJECTIVES: This analysis sought to investigate the complementary effect of thienopyridine pretreatment and platelet glycoprotein (GP) IIb/IIIa integrin blockade in coronary stent intervention. BACKGROUND: Definitive evidence supporting combined antiplatelet therapy consisting of thienopyridine pretreatment and GP IIb/IIIa receptor blockade in patients undergoing percutaneous coronary intervention (PCI) with stent implantation is limited. METHODS: We retrospectively analyzed clinical outcomes by thienopyridine use in the 2,040 patients randomized to eptifibatide or placebo who underwent PCI in the ESPRIT trial. RESULTS: A total of 901 patients received a loading dose of thienopyridine before PCI (group 1), 123 received thienopyridine pretreatment without a loading dose (group 2), and 1,016 were not treated with thienopyridine before PCI (group 3). The composite incidence of death or myocardial infarction at 30 days was significantly lower in group 1 than in groups 2 and 3 combined (OR, 0.71 [95%CI, 0.52-0.99]; P = 0.0417). A similar trend was seen for the composite of death, myocardial infarction, or urgent target vessel revascularization (unadjusted OR, 0.77 [0.57-1.05]; P = 0.1025). After adjusting for baseline characteristics, these differences were no longer significant. No interactions were identified with eptifibatide assignment for any of the group comparisons. CONCLUSIONS: Pretreatment with a loading dose of thienopyridine lowers the rate of ischemic complications regardless of treatment with a GP IIb/IIIa inhibitor. Conversely, the efficacy of eptifibatide is maintained whether or not a loading dose of a thienopyridine is administered. Optimal outcomes are achieved in patients receiving thienopyridine pretreatment along with platelet GP IIb/IIIa inhibitor therapy.

Duke Scholars

Published In

Catheter Cardiovasc Interv

DOI

ISSN

1522-1946

Publication Date

July 1, 2007

Volume

70

Issue

1

Start / End Page

43 / 50

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Ticlopidine
  • Stents
  • Risk Assessment
  • Retrospective Studies
  • Pyridines
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Platelet Aggregation Inhibitors
  • Peptides
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Dery, J.-P., Campbell, M. E., Mathias, J., Pieper, K. S., Harrington, R. A., Madan, M., … ESPRIT Investigators, . (2007). Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial. Catheter Cardiovasc Interv, 70(1), 43–50. https://doi.org/10.1002/ccd.21059
Dery, Jean-Pierre, Mark E. Campbell, Jasmine Mathias, Karen S. Pieper, Robert A. Harrington, Mina Madan, C Michael Gibson, et al. “Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.Catheter Cardiovasc Interv 70, no. 1 (July 1, 2007): 43–50. https://doi.org/10.1002/ccd.21059.
Dery J-P, Campbell ME, Mathias J, Pieper KS, Harrington RA, Madan M, et al. Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial. Catheter Cardiovasc Interv. 2007 Jul 1;70(1):43–50.
Dery, Jean-Pierre, et al. “Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.Catheter Cardiovasc Interv, vol. 70, no. 1, July 2007, pp. 43–50. Pubmed, doi:10.1002/ccd.21059.
Dery J-P, Campbell ME, Mathias J, Pieper KS, Harrington RA, Madan M, Gibson CM, Tolleson TR, O’Shea JC, Tcheng JE, ESPRIT Investigators. Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial. Catheter Cardiovasc Interv. 2007 Jul 1;70(1):43–50.
Journal cover image

Published In

Catheter Cardiovasc Interv

DOI

ISSN

1522-1946

Publication Date

July 1, 2007

Volume

70

Issue

1

Start / End Page

43 / 50

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Ticlopidine
  • Stents
  • Risk Assessment
  • Retrospective Studies
  • Pyridines
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Platelet Aggregation Inhibitors
  • Peptides